206 related articles for article (PubMed ID: 22811710)
21. Clinicopathologic and prognostic significance of SATB1 in cutaneous malignant melanoma.
Chen H; Takahara M; Oba J; Xie L; Chiba T; Takeuchi S; Tu Y; Nakahara T; Uchi H; Moroi Y; Furue M
J Dermatol Sci; 2011 Oct; 64(1):39-44. PubMed ID: 21767935
[TBL] [Abstract][Full Text] [Related]
22. Cell proliferation in cutaneous malignant melanoma: relationship with neoplastic progression.
Piérard GE
ISRN Dermatol; 2012; 2012():828146. PubMed ID: 22363864
[TBL] [Abstract][Full Text] [Related]
23. Malignant melanoma: reduced risk associated with early childbearing and multiparity.
Lambe M; Thörn M; Sparén P; Bergström R; Adami HO
Melanoma Res; 1996 Apr; 6(2):147-53. PubMed ID: 8791273
[TBL] [Abstract][Full Text] [Related]
24. Stage-specific direct health care costs in patients with cutaneous malignant melanoma.
Lyth J; Carstensen J; Synnerstad I; Lindholm C
J Eur Acad Dermatol Venereol; 2016 May; 30(5):789-93. PubMed ID: 25807966
[TBL] [Abstract][Full Text] [Related]
25. Collagenase-3 (MMP-13) expression in cutaneous malignant melanoma.
Corte MD; Gonzalez LO; Corte MG; Quintela I; Pidal I; Bongera M; Vizoso F
Int J Biol Markers; 2005; 20(4):242-8. PubMed ID: 16398406
[TBL] [Abstract][Full Text] [Related]
26. Vascular-Associated Muc4/Vwf Co-Localization in Human Conjunctival Malignant Melanoma Specimens-Tumor Metastasis by Migration?
Kakkassery V; Winterhalter S; Nick AC; Joachim SC; Joussen AM; Kociok N
Curr Eye Res; 2017 Oct; 42(10):1382-1388. PubMed ID: 28622066
[TBL] [Abstract][Full Text] [Related]
27. GSTO1 regards as a meritorious regulator in cutaneous malignant melanoma cells.
Wang LK; Yue HL; Peng XJ; Zhang SJ
Mol Cell Probes; 2019 Dec; 48():101449. PubMed ID: 31525447
[TBL] [Abstract][Full Text] [Related]
28. Cutaneous malignant melanoma incidence and mortality trends in Canada: A comprehensive population-based study.
Ghazawi FM; Cyr J; Darwich R; Le M; Rahme E; Moreau L; Netchiporouk E; Zubarev A; Roshdy O; Glassman SJ; Sasseville D; Litvinov IV
J Am Acad Dermatol; 2019 Feb; 80(2):448-459. PubMed ID: 30092328
[TBL] [Abstract][Full Text] [Related]
29. [Clinico-genetic aspects of cutaneous melanoma. II. Interconnection and pathogenetic commonality with dysplastic nevus syndrome].
Kharkevich GIu; Kazubskaia TP; Agapova RK; Musatov VK; Trubnikov VI; Demidov LV; Gar'kavtseva RF
Genetika; 1995 Nov; 31(11):1562-5. PubMed ID: 8666223
[TBL] [Abstract][Full Text] [Related]
30. The prognostic significance of basic fibroblast growth factor in cutaneous malignant melanoma.
al-Alousi S; Barnhill R; Blessing K; Barksdale S
J Cutan Pathol; 1996 Dec; 23(6):506-10. PubMed ID: 9001980
[TBL] [Abstract][Full Text] [Related]
31. Correlation among metallothionein expression, intratumoural macrophage infiltration and the risk of metastasis in human cutaneous malignant melanoma.
Emri E; Egervari K; Varvolgyi T; Rozsa D; Miko E; Dezso B; Veres I; Mehes G; Emri G; Remenyik E
J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e320-7. PubMed ID: 22817475
[TBL] [Abstract][Full Text] [Related]
32. In vivo skin fluorescence imaging in young Caucasian adults with early malignant melanomas.
Piérard GE; Hermanns-Lê T; Piérard SL; Dewalque L; Charlier C; Piérard-Franchimont C; Delvenne P
Clin Cosmet Investig Dermatol; 2014; 7():225-30. PubMed ID: 25187731
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological Characteristics and Short-Term Survival Analyses of Cutaneous Malignant Melanoma.
Ullah F; Jamshed M; Shakeel O; Khalid U; Khan R; Dhanani R; Mansoor R; Ullah S; Hussain R
Cureus; 2020 Aug; 12(8):e9868. PubMed ID: 32963909
[TBL] [Abstract][Full Text] [Related]
34. Extra nodal growth as a prognostic factor in malignant melanoma.
Koopal SA; Tiebosch AT; Daryanani D; Plukker JT; Hoekstra HJ
Eur J Surg Oncol; 2005 Feb; 31(1):88-94. PubMed ID: 15642432
[TBL] [Abstract][Full Text] [Related]
35. Coordinated targeting of MMP-2/MMP-9 by miR-296-3p/FOXCUT exerts tumor-suppressing effects in choroidal malignant melanoma.
Wang X; Hu Y; Cui J; Zhou Y; Chen L
Mol Cell Biochem; 2018 Aug; 445(1-2):25-33. PubMed ID: 29260433
[TBL] [Abstract][Full Text] [Related]
36. Melanocytic nevi and risk of cutaneous malignant melanoma in southern Spain.
Ródenas JM; Delgado-Rodríguez M; Farinas-Alvarez C; Herranz MT; Serrano S
Am J Epidemiol; 1997 Jun; 145(11):1020-9. PubMed ID: 9169911
[TBL] [Abstract][Full Text] [Related]
37. The impact of autoimmune diseases on the incidence and prognosis of cutaneous malignant melanoma.
Kaae J; Wohlfahrt J; Boyd HA; Wulf HC; Biggar RJ; Melbye M
Cancer Epidemiol Biomarkers Prev; 2007 Sep; 16(9):1840-4. PubMed ID: 17855703
[TBL] [Abstract][Full Text] [Related]
38. Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity.
Goldstein AM; Dracopoli NC; Engelstein M; Fraser MC; Clark WH; Tucker MA
Am J Hum Genet; 1994 Mar; 54(3):489-96. PubMed ID: 8116618
[TBL] [Abstract][Full Text] [Related]
39. Epidemiologic evidence for the role of melanocytic nevi as risk markers and direct precursors of cutaneous malignant melanoma. Results of a case control study in melanoma patients and nonmelanoma control subjects.
Krüger S; Garbe C; Büttner P; Stadler R; Guggenmoos-Holzmann I; Orfanos CE
J Am Acad Dermatol; 1992 Jun; 26(6):920-6. PubMed ID: 1607409
[TBL] [Abstract][Full Text] [Related]
40. TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma.
Naeser Y; Helgadottir H; Brandberg Y; Hansson J; Bagge RO; Elander NO; Ingvar C; Isaksson K; Flygare P; Nilsson C; Jakobsson F; Del Val Munoz O; Valachis A; Jansson M; Sparring C; Ohlsson L; Dyrke U; Papantoniou D; Sundin A; Ullenhag GJ
BMC Cancer; 2020 Dec; 20(1):1197. PubMed ID: 33287744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
